Go Pro
→ Iran War Shock: What I Was Told In That Private Meeting (From Banyan Hill Publishing) (Ad)tc pixel Free AGY Stock Alerts

Allergy Therapeutics (AGY) Competitors

Allergy Therapeutics logo
GBX 5.98 0.00 (0.00%)
As of 07/31/2026 12:00 PM Eastern
Compare

AGY vs. AMYT, APH, BXP, ANCR, and VLG

Should you buy Allergy Therapeutics stock or one of its competitors? MarketBeat compares Allergy Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Allergy Therapeutics include Amryt Pharma (AMYT), Alliance Pharma (APH), Beximco Pharmaceuticals (BXP), Animalcare Group (ANCR), and Venture Life Group (VLG).

How does Allergy Therapeutics compare to Amryt Pharma?

Amryt Pharma (LON:AMYT) and Allergy Therapeutics (LON:AGY) are both small-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, media sentiment, risk, earnings, profitability, valuation, dividends and institutional ownership.

Amryt Pharma has a net margin of 0.00% compared to Allergy Therapeutics' net margin of -85.46%. Allergy Therapeutics' return on equity of 409.00% beat Amryt Pharma's return on equity.

Company Net Margins Return on Equity Return on Assets
Amryt PharmaN/A N/A N/A
Allergy Therapeutics -85.46%409.00%-34.76%

0.0% of Allergy Therapeutics shares are held by institutional investors. 3.6% of Allergy Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Amryt Pharma has higher revenue and earnings than Allergy Therapeutics. Allergy Therapeutics is trading at a lower price-to-earnings ratio than Amryt Pharma, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Amryt Pharma£210.24M0.00N/A-£33.00N/A
Allergy Therapeutics£57.29M6.61-£52.59M-£0.97N/A

In the previous week, Amryt Pharma's average media sentiment score of 0.00 equaled Allergy Therapeutics'average media sentiment score.

Company Overall Sentiment
Amryt Pharma Neutral
Allergy Therapeutics Neutral

Summary

Amryt Pharma and Allergy Therapeutics tied by winning 4 of the 8 factors compared between the two stocks.

How does Allergy Therapeutics compare to Alliance Pharma?

Allergy Therapeutics (LON:AGY) and Alliance Pharma (LON:APH) are both small-cap healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, valuation, media sentiment, risk, analyst recommendations, earnings, dividends and profitability.

Allergy Therapeutics has a beta of 0.872, indicating that its share price is 13% less volatile than the broader market. Comparatively, Alliance Pharma has a beta of 0.67, indicating that its share price is 33% less volatile than the broader market.

0.0% of Allergy Therapeutics shares are owned by institutional investors. Comparatively, 66.3% of Alliance Pharma shares are owned by institutional investors. 3.6% of Allergy Therapeutics shares are owned by company insiders. Comparatively, 12.0% of Alliance Pharma shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Alliance Pharma has a net margin of -6.00% compared to Allergy Therapeutics' net margin of -85.46%. Allergy Therapeutics' return on equity of 409.00% beat Alliance Pharma's return on equity.

Company Net Margins Return on Equity Return on Assets
Allergy Therapeutics-85.46% 409.00% -34.76%
Alliance Pharma -6.00%-5.04%5.98%

Alliance Pharma has higher revenue and earnings than Allergy Therapeutics. Alliance Pharma is trading at a lower price-to-earnings ratio than Allergy Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Allergy Therapeutics£57.29M6.61-£52.59M-£0.97N/A
Alliance Pharma£183.50M1.91-£33.65M-£6.20N/A

In the previous week, Allergy Therapeutics' average media sentiment score of 0.00 equaled Alliance Pharma'saverage media sentiment score.

Company Overall Sentiment
Allergy Therapeutics Neutral
Alliance Pharma Neutral

Summary

Alliance Pharma beats Allergy Therapeutics on 6 of the 11 factors compared between the two stocks.

How does Allergy Therapeutics compare to Beximco Pharmaceuticals?

Beximco Pharmaceuticals (LON:BXP) and Allergy Therapeutics (LON:AGY) are both small-cap healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their analyst recommendations, profitability, valuation, institutional ownership, earnings, dividends, risk and media sentiment.

Beximco Pharmaceuticals has a beta of 0.251, meaning that its stock price is 75% less volatile than the broader market. Comparatively, Allergy Therapeutics has a beta of 0.872, meaning that its stock price is 13% less volatile than the broader market.

Beximco Pharmaceuticals has a net margin of 16.76% compared to Allergy Therapeutics' net margin of -85.46%. Allergy Therapeutics' return on equity of 409.00% beat Beximco Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
Beximco Pharmaceuticals16.76% 11.99% 6.97%
Allergy Therapeutics -85.46%409.00%-34.76%

In the previous week, Beximco Pharmaceuticals had 1 more articles in the media than Allergy Therapeutics. MarketBeat recorded 1 mentions for Beximco Pharmaceuticals and 0 mentions for Allergy Therapeutics. Beximco Pharmaceuticals' average media sentiment score of 0.00 equaled Allergy Therapeutics'average media sentiment score.

Company Overall Sentiment
Beximco Pharmaceuticals Neutral
Allergy Therapeutics Neutral

Beximco Pharmaceuticals has higher revenue and earnings than Allergy Therapeutics. Allergy Therapeutics is trading at a lower price-to-earnings ratio than Beximco Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Beximco Pharmaceuticals£53.93B0.00£970.84B£1.94 thousand0.03
Allergy Therapeutics£57.29M6.61-£52.59M-£0.97N/A

0.3% of Beximco Pharmaceuticals shares are held by institutional investors. Comparatively, 0.0% of Allergy Therapeutics shares are held by institutional investors. 4.2% of Beximco Pharmaceuticals shares are held by insiders. Comparatively, 3.6% of Allergy Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Summary

Beximco Pharmaceuticals beats Allergy Therapeutics on 9 of the 12 factors compared between the two stocks.

How does Allergy Therapeutics compare to Animalcare Group?

Allergy Therapeutics (LON:AGY) and Animalcare Group (LON:ANCR) are both small-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their valuation, earnings, profitability, media sentiment, dividends, analyst recommendations, risk and institutional ownership.

Animalcare Group has higher revenue and earnings than Allergy Therapeutics. Allergy Therapeutics is trading at a lower price-to-earnings ratio than Animalcare Group, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Allergy Therapeutics£57.29M6.61-£52.59M-£0.97N/A
Animalcare Group£89.11M2.60£36.55M£7.3045.89

0.0% of Allergy Therapeutics shares are owned by institutional investors. Comparatively, 14.3% of Animalcare Group shares are owned by institutional investors. 3.6% of Allergy Therapeutics shares are owned by insiders. Comparatively, 30.1% of Animalcare Group shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Allergy Therapeutics has a beta of 0.872, meaning that its stock price is 13% less volatile than the broader market. Comparatively, Animalcare Group has a beta of 0.67, meaning that its stock price is 33% less volatile than the broader market.

Animalcare Group has a net margin of 5.70% compared to Allergy Therapeutics' net margin of -85.46%. Allergy Therapeutics' return on equity of 409.00% beat Animalcare Group's return on equity.

Company Net Margins Return on Equity Return on Assets
Allergy Therapeutics-85.46% 409.00% -34.76%
Animalcare Group 5.70%4.46%2.97%

In the previous week, Allergy Therapeutics' average media sentiment score of 0.00 equaled Animalcare Group'saverage media sentiment score.

Company Overall Sentiment
Allergy Therapeutics Neutral
Animalcare Group Neutral

Summary

Animalcare Group beats Allergy Therapeutics on 8 of the 11 factors compared between the two stocks.

How does Allergy Therapeutics compare to Venture Life Group?

Allergy Therapeutics (LON:AGY) and Venture Life Group (LON:VLG) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their earnings, dividends, valuation, profitability, risk, analyst recommendations, media sentiment and institutional ownership.

0.0% of Allergy Therapeutics shares are held by institutional investors. Comparatively, 21.9% of Venture Life Group shares are held by institutional investors. 3.6% of Allergy Therapeutics shares are held by insiders. Comparatively, 7.5% of Venture Life Group shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Venture Life Group has a net margin of 17.42% compared to Allergy Therapeutics' net margin of -85.46%. Allergy Therapeutics' return on equity of 409.00% beat Venture Life Group's return on equity.

Company Net Margins Return on Equity Return on Assets
Allergy Therapeutics-85.46% 409.00% -34.76%
Venture Life Group 17.42%7.82%1.56%

Allergy Therapeutics has a beta of 0.872, suggesting that its share price is 13% less volatile than the broader market. Comparatively, Venture Life Group has a beta of 0.217, suggesting that its share price is 78% less volatile than the broader market.

In the previous week, Venture Life Group had 2 more articles in the media than Allergy Therapeutics. MarketBeat recorded 2 mentions for Venture Life Group and 0 mentions for Allergy Therapeutics. Venture Life Group's average media sentiment score of 0.49 beat Allergy Therapeutics' score of 0.00 indicating that Venture Life Group is being referred to more favorably in the news media.

Company Overall Sentiment
Allergy Therapeutics Neutral
Venture Life Group Neutral

Venture Life Group has lower revenue, but higher earnings than Allergy Therapeutics. Allergy Therapeutics is trading at a lower price-to-earnings ratio than Venture Life Group, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Allergy Therapeutics£57.29M6.61-£52.59M-£0.97N/A
Venture Life Group£35.17M2.40£747.21K£4.3715.93

Summary

Venture Life Group beats Allergy Therapeutics on 9 of the 13 factors compared between the two stocks.

Get Allergy Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for AGY and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

Media Sentiment Over Time

This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

AGY vs. The Competition

Export
MetricAllergy TherapeuticsPharmaceuticals IndustryHealthcare SectorLON Exchange
Market Cap£378.69M£11.74B£6.86B£2.82B
Dividend Yield8.33%2.73%2.59%6.15%
P/E Ratio-6.16799.05282.27368.29
Price / Sales6.61749.34590.9183,501.30
Price / Cash3.6614.8228.6027.89
Price / Book60.6010.3910.937.04
Net Income-£52.59M£2.82B£3.49B£5.89B
7 Day Performance10.74%-0.18%-0.64%6.05%
1 Month Performance-9.39%-4.04%-3.78%-0.22%
1 Year Performance-25.25%156.15%61.99%63.72%

Allergy Therapeutics Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
AGY
Allergy Therapeutics
N/AGBX 5.98
flat		N/A-25.3%£378.69M£57.29MN/A612
AMYT
Amryt Pharma
N/AN/AN/AN/A£457.11M£210.24MN/A290
APH
Alliance Pharma
N/AGBX 64.70
flat		N/AN/A£350.32M£183.50MN/A91,000
BXP
Beximco Pharmaceuticals
N/AGBX 53.70
+3.3%		N/A+35.9%£239.56M£53.93B0.035,500
ANCR
Animalcare Group
N/AGBX 333.58
+0.0%		N/AN/A£230.33M£89.11M45.70220

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (LON:AGY) was last updated on 8/3/2026 by MarketBeat.com Staff.
From Our Partners
ALERT: Drop these 5 stocks before the market opens tomorrow!
The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings researc...
Weiss Ratings | Sponsoredtc pixel
Louis Navellier: My #1 AI stock for 2026 (name & ticker inside)
Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...
InvestorPlace | Sponsoredtc pixel
Trump Takes Emergency Action - Plus Elon Musk's New Venture
Elon Musk has quietly launched a new venture - one that has nothing to do with rockets, EVs, or Neuralink. Tru...
Altimetry | Sponsoredtc pixel
Ready to give options a try? Your first trade (Ticker included) -INSIDE
Tired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...
Base Camp Trading | Sponsoredtc pixel
My top 3 AI picks for the next decade
Alexander Green bought Apple in 1996, recommended Nvidia at a split-adjusted 66 cents in 2004, and picked up A...
The Oxford Club | Sponsoredtc pixel
Elon's new "super startup"
Adam O'Dell - the analyst who recommended Palantir before it became the top S&P 500 performer - has identified...
Banyan Hill Publishing | Sponsoredtc pixel
Where to Put $100 Before Trump's New Tech Law Rolls Out
The Financial Times says a new tech law puts America 'on the verge of a financial revolution.' Yahoo Finance e...
Brownstone Research | Sponsoredtc pixel
“The unseen winner of the AI race” is not SpaceX
Marc Chaikin - the analyst who called Nvidia before its historic run - says a tech firm labeled 'the unseen wi...
Chaikin Analytics | Sponsoredtc pixel